You are here: Industry Insights > Japan

News List

Japan approves Rakuten Medical's ASP-1929 to treat cancer biospectrumasia
April 10, 2019
ASP-1929 received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of head and neck squamous cell carcinomas (HNSCC) in the first quarter of 2018.
Japan grants Sakigake designation to Eisai’s novel FGFR biospectrumasia
April 08, 2019
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.
Forxiga approved in Japan for type-1 diabetes worldpharmanews
March 28, 2019
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D).
Lupin, YL Biologics receive nod to market rheumatoid arthritis drug in Japan expressbpd
March 27, 2019
Biosimilar Etanercept is indicated to treat moderate to severe rheumatoid arthritis (RA) and juvenile idiopathic arthritis
Aprecia, CMIC to bring 3DP pharmaceutical products to Japan biospectrumasia
March 15, 2019
Aprecia is the world's first and only commercial-stage manufacturer of three-dimensionally printed pharmaceuticals.
Avita Medical to commercialize wounds treatment device in Japan biospectrumasia
March 08, 2019
Australia based AVITA Medical, regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Autologous Cell Harvesting Device (RECELL® System) for the treatment of burns and oth
Bayer files prostate cancer drug darolutamide in Japan pharmaphorum
March 07, 2019
Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.
Japan solid dose market predicted to bloom in 2019 cphi-online
March 07, 2019
Executives predict Japan to be the second fastest growing mature market for solid dose drugs in 2019, and the second fastest overall country for biologicals growth.
Pfizer Japan drawn into valsartan recall after finding API from Mylan is tainted fiercepharma
February 24, 2019
The global recall of valsartan has now extended to Pfizer and to Japan, via Mylan and India.
Japan second fastest pharma growth in 2019- CPhI Report biospectrumasia
February 22, 2019
Bio and generic demand driving increased internationalisation and renewed optimism amongst industry

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page